HomeAI · summaries
Storia in 10 fonti
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect the deal to conclude in the third quarter of this year.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
- ·
benzinga.com
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)
AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
